Phase II randomized preoperative window-of-opportunity study of the PI3K inhibitor pictilisib plus anastrozole compared with anastrozole alone in patients with estrogen receptor-positive breast cancer

Peter Schmid (Lead / Corresponding author), Sarah E. Pinder, Duncan Wheatley, Jane Macaskill, Charles Zammit, Jennifer Hu, Robert Price, Nigel Bundred, Sirwan Hadad, Alice Shia, Shah Jalal Sarker, Louise Lim, Patrycja Gazinska, Natalie Woodman, Darren Korbie, Matt Trau, Paul Mainwaring, Steven Gendreau, Mark R. Lackner, Mika DerynckTimothy R. Wilson, Hannah Butler, Gemma Earl, Peter Parker, Arnie Purushotham, Alastair Thompson

    Research output: Contribution to journalArticlepeer-review

    77 Citations (Scopus)
    255 Downloads (Pure)

    Fingerprint

    Dive into the research topics of 'Phase II randomized preoperative window-of-opportunity study of the PI3K inhibitor pictilisib plus anastrozole compared with anastrozole alone in patients with estrogen receptor-positive breast cancer'. Together they form a unique fingerprint.

    Keyphrases

    Medicine and Dentistry

    Pharmacology, Toxicology and Pharmaceutical Science

    Neuroscience